Skip to Main Content

Author Details

Dietger Niederwieser
University of Leipzig
1982
597
95
PMIDPaper TitleJournal TitlePublished Year
37280449Radiation hazards of the Ukraine nuclear power plants: how can international blood and marrow stem cell transplant societies help?Ann Hematol2024
34688625Strategic priorities for hematopoietic stem cell transplantation in the EMRO region.Hematol Oncol Stem Cell Ther2023
35381077Impact of IDH1 and IDH2 mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation.Blood Adv2023
36990624Endemic or regionally limited parasitic and fungal infections in haematopoietic stem-cell transplantation recipients: a Worldwide Network for Blood and Marrow Transplantation (WBMT) Review.Lancet Haematol2023
36990623Endemic or regionally limited bacterial and viral infections in haematopoietic stem-cell transplantation recipients: a Worldwide Network for Blood and Marrow Transplantation (WBMT) Review.Lancet Haematol2023
36695874Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study.Ann Hematol2023
36403897Prognostic Impact of Organomegaly in Mastocytosis: An Analysis of the European Competence Network on Mastocytosis.J Allergy Clin Immunol Pract2023
36572384An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia.Transplant Cell Ther2023
36827620Prognostic value of blood biomarkers in steroid-refractory or steroid-dependent acute graft-versus-host disease: a REACH2 analysis.Blood2023
35987926Impact of the changing landscape of induction therapy prior to autologous stem cell transplantation in 540 newly diagnosed myeloma patients: a retrospective real-world study.J Cancer Res Clin Oncol2023
36195769A high hematopoietic cell transplantation comorbidity Index (HCT-CI) does not impair outcomes after non-myeloablative allogeneic stem cell transplantation in acute myeloid leukemia patients 60 years or older.Bone Marrow Transplant2023
34316017Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results.Leukemia2022
35617104Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trial.Am J Hematol2022
35801531Analysis of stem cell collections in adult patients with Ewing sarcoma.Transfusion2022
35543293A review of the totality of evidence in the development of ABP 798, a rituximab biosimilar.Immunotherapy2022
35797463Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.Blood2022
35605254Impact of MRD status in patients with AML undergoing allogeneic stem cell transplantation in the first vs the second remission.Blood Adv2022
35664207Couples Coping With Hematological Cancer: Support Within and Outside the Couple - Findings From a Qualitative Analysis of Dyadic Interviews.Front Psychol2022
35418351Current Status of CPX-351 Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome.Clin Lymphoma Myeloma Leuk2022
35413459Worldwide Network for Blood and Marrow Transplantation Special Article on Key Elements in Quality and Accreditation in Hematopoietic Stem Cell Transplantation and Cellular Therapy.Transplant Cell Ther2022
37220608The activities and regulatory landscape of cellular therapies including hematopoietic cell transplantation in the world.Blood Cell Ther2022
36105914Efficacy and safety of ruxolitinib in patients with myelofibrosis and low platelet count (50⿿ÿ⿿10<sup>9</sup>/L to &lt;100⿿ÿ⿿10<sup>9</sup>/L) at baseline: the final analysis of EXPAND.Ther Adv Hematol2022
35901845Suitability of haematopoietic cell donors: updated consensus recommendations from the WBMT standing committee on donor issues.Lancet Haematol2022
34952929Results of a multicenter phase I/II trial of TCRαβ and CD19-depleted haploidentical hematopoietic stem cell transplantation for adult and pediatric patients.Bone Marrow Transplant2022
35181744Prospective phase II study of preemptive chimerism-driven reduction of immunosuppression after non-myeloablative conditioning-Eudract #: 2007-002420-15.Bone Marrow Transplant2022
34893987Stem-cell mobilization of healthy sibling donors with pegfilgrastim-A prospective open-label phase II trial (EudraCT no: 2005-004971-39).Transfusion2022
34382386One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors.Haematologica2022
33009514Impact of patient: donor HLA disparity on reduced-intensity-conditioned allogeneic stem cell transplants from HLA mismatched unrelated donors for AML: from the ALWP of the EBMT.Bone Marrow Transplant2021
33829299Allogeneic stem cell transplantation for mantle cell lymphoma-update of the prospective trials of the East German Study Group Hematology/Oncology (OSHO#60 and #74).Ann Hematol2021
33654204Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial.Leukemia2021
33514925The Chinese HCT survey: a non-manipulated haploidentical transplantation procedure makes a novel contribution to data sharing within the regional and global transplant registries and to worldwide knowledge.Bone Marrow Transplant2021
33764805Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes.J Clin Oncol2021
33927190Prognostic relevance of remission and measurable residual disease status in AML patients prior to reduced intensity or non-myeloablative allogeneic stem cell transplantation.Blood Cancer J2021
33811773Clinical value of the measurable residual disease status within the ELN2017 risk groups in AML patients undergoing allogeneic stem cell transplantation.Am J Hematol2021
33781537Changes in Hematopoietic Cell Transplantation Practices in Response to COVID-19: A Survey from the Worldwide Network for Blood &amp; Marrow Transplantation.Transplant Cell Ther2021
33781535Worldwide Network for Blood and Marrow Transplantation (WBMT) Recommendations Regarding Essential Medications Required To Establish An Early Stage Hematopoietic Cell Transplantation Program.Transplant Cell Ther2021
33615146Nutritional Status at Diagnosis and Pre-transplant Weight Loss Impact Outcomes of Acute Myeloid Leukemia Patients Following Allogeneic Stem Cell Transplantation.Hemasphere2021
33603743Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies.Front Immunol2021
34889391Increasing access to allogeneic hematopoietic cell transplant: an international perspective.Hematology Am Soc Hematol Educ Program2021
35122024Hotspot DNMT3A mutations in clonal hematopoiesis and acute myeloid leukemia sensitize cells to azacytidine via viral mimicry response.Nat Cancer2021
34956873Case Report: Graft <i>Versus</i> Tumor Effect After Non-Myeloablative Allogeneic Stem-Cell Transplantation in a Patient With Brentuximab-Vedotin Refractory Sezary Syndrome.Front Oncol2021
34529106Correction to: Allogeneic hematopoietic stem cell transplantation improves longâ¿¿term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials.Ann Hematol2021
34670273The diagnostic red blood cell distribution width as a prognostic factor in acute myeloid leukemia.Blood Adv2021
34267355Measurable residual disease of canonical versus non-canonical DNMT3A, TET2, or ASXL1 mutations in AML at stem cell transplantation.Bone Marrow Transplant2021
34289154Clinical implications of SRSF2 mutations in AML patients undergoing allogeneic stem cell transplantation.Am J Hematol2021
34232360Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials.Ann Hematol2021
34138638Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis.J Clin Oncol2021
33355646Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and/or Ifosfamide-Refractory Soft Tissue Sarcoma: Final Results of the PAPAGEMO Phase 2 Randomized Clinical Trial.JAMA Oncol2021
33208914ELN risk stratification and outcomes in secondary and therapy-related AML patients consolidated with allogeneic stem cell transplantation.Bone Marrow Transplant2021
30848313[Meningococcal sepsis without cerebrospinal fluid abnormalities under treatment with eculizumab].Med Klin Intensivmed Notfmed2020
  • 1 - 50 of 597

Recommended Authors

Lohith Gowda
Yale Cancer Center and Yale School of Medicine
Career Start Year 2018
Number of shared co-authors 1
Molly Maloy
Memorial Sloan Kettering Cancer Center
Career Start Year 2013
Number of shared co-authors 1
Sawa Ito
University of Pittsburgh
Career Start Year 2013
Number of shared co-authors 0
Aarthi Shenoy
MedStar Washington Hospital Center
Career Start Year 2006
Number of shared co-authors 0
Marlise R Luskin
Dana-Farber Cancer Institute
Career Start Year 2005
Number of shared co-authors 17
Tara L Lin
University of Kansas Medical Center
Career Start Year 2004
Number of shared co-authors 8
Laura F Newell
Oregon Health and Science University
Career Start Year 2003
Number of shared co-authors 8
Christopher R Cogle
College of Medicine, University of Florida
Career Start Year 2003
Number of shared co-authors 8
Eneida R Nemecek
Oregon Health Sciences University
Career Start Year 2002
Number of shared co-authors 7
Ivan Pasic
Princess Margaret Cancer Centre
Career Start Year 2001
Number of shared co-authors 0
Lionel Ad??s
Assistance Publique des Hopitaux de Paris (AP-HP)
Career Start Year 1998
Number of shared co-authors 11
Emmanuel Raffoux
Universite Paris Diderot
Career Start Year 1998
Number of shared co-authors 14
David A Rizzieri
Duke University Medical Center
Career Start Year 1995
Number of shared co-authors 15
Gabrielle Meyers
Oregon Health and Science University
Career Start Year 1994
Number of shared co-authors 3
Michael W Becker
James P. Wilmot Cancer Institute, University of Rochester Medical Center Rochester
Career Start Year 1992
Number of shared co-authors 2
Peter Westervelt
Washington University School of Medicine
Career Start Year 1990
Number of shared co-authors 12
Claude Gardin
Avicenne Hospital
Career Start Year 1990
Number of shared co-authors 3
Jose A Cancelas
Cincinnati Children's Hospital Medical Center
Career Start Year 1990
Number of shared co-authors 4
Koen van Besien
University Hospitals of Cleveland
Career Start Year 1988
Number of shared co-authors 9
Steven Z Pavletic
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 1987
Number of shared co-authors 7
Clayton A Smith
University of Colorado, Aurora CO.
Career Start Year 1987
Number of shared co-authors 2
Robert H Collins
University of Texas Southwestern Medical Center
Career Start Year 1987
Number of shared co-authors 15
Alan S Wayne
Cancer and Blood Disease Institute, Children's Hospital Los Angeles
Career Start Year 1986
Number of shared co-authors 4
Denis-Claude Roy
Universite de Montreal
Career Start Year 1985
Number of shared co-authors 7
Kenneth B Miller
Tufts Medical Center
Career Start Year 1981
Number of shared co-authors 3
Stefan Burdach
Technische Universitat Munchen
Career Start Year 1981
Number of shared co-authors 6
Ulrich D??hrsen
University Hospital Essen, University of Duisburg-Essen
Career Start Year 1979
Number of shared co-authors 11
John F DiPersio
Washington University School of Medicine
Career Start Year 1978
Number of shared co-authors 21
Curt I Civin
Center for Stem Cell Biology & Regenerative Medicine and.
Career Start Year 1976
Number of shared co-authors 3
Jerome Ritz
Dana-Farber Cancer Institute, Harvard Medical School, Brigham and Women's Hospital
Career Start Year 1976
Number of shared co-authors 10

Collaborators

Thoralf Lange
Hospital Weissenfels
Co-authored papers 59
Michael W Deininger
University of Utah Huntsman Cancer Institute
Co-authored papers 29
Hagop Kantarjian
The University of Texas MD Anderson Cancer Center
Co-authored papers 11
Richard M Stone
Dana Farber Cancer Institute
Co-authored papers 10
Martin S Tallman
Memorial Sloan-Kettering Cancer Center
Co-authored papers 9
Richard T Maziarz
Oregon Health & Science University
Co-authored papers 9
Brian J Druker
Oregon Health & Science University
Co-authored papers 7
Jerald P Radich
Fred Hutchinson Cancer Center
Co-authored papers 7
Nikolas von Bubnoff
University Hospital of Schleswig-Holstein
Co-authored papers 7
Jorge Cortes
Georgia Cancer Center
Co-authored papers 6
Ann-Kathrin Eisfeld
The Ohio State University Comprehensive Cancer Center
Co-authored papers 5
Luca Malcovati
University of Pavia & S. Matteo Hospital
Co-authored papers 5
Herv?? Dombret
Institut de Recherche Saint-Louis, Universite de Paris
Co-authored papers 5
Bruno C Medeiros
AbbVie Inc.
Co-authored papers 5
Jason Gotlib
Stanford University School of Medicine
Co-authored papers 4
Michael Heuser
Hannover Medical School
Co-authored papers 4
Daniel G Tenen
Harvard Stem Cell Institute, Harvard Medical School
Co-authored papers 4
Leslie Lehmann
Dana Farber Cancer Institute/Boston Children's Hospital
Co-authored papers 3
Ines Kovacs
Co-authored papers 3
Wolfgang E Berdel
University Hospital Munster
Co-authored papers 3
Torsten Haferlach
Taussig Cancer Institute, Cleveland Clinic
Co-authored papers 3
Dong Wook Kim
Yonsei University College of Medicine, Republic of Korea S. Biomedics Co.
Co-authored papers 3
Effie W Petersdorf
Fred Hutchinson Cancer Center
Co-authored papers 3
Sandra Otto
Co-authored papers 3
Susan Geyer
Division of Clinical Trials and Biostatistics, Mayo Clinic
Co-authored papers 3
Joop H Jansen
Co-authored papers 3
Christoph R??llig
Hopp Children's Cancer Center (KiTZ)
Co-authored papers 3
Byung Park
Oregon Health & Science University
Co-authored papers 2
Alberto Zambelli
IRCCS Humanitas Research Hospital
Co-authored papers 2
Thomas Klingebiel
Co-authored papers 2
Release 1.2